From a recent study, it is demonstrated that 100 mg or 300 mg intravenous eptinezumab is safe and efficient for migraine prevention in adult patients suffering from chronic migraine.

In this study, patients were given up to two intravenous doses of eptinezumab or placebo break by 12 weeks. The daily migraine and headache endpoints were recorded by the patients. 

Table: Decrease in mean monthly migraine days

The migraine responder rates became better after a second dose, with more eptinezumab treated patients. The percentages of patients who became better on patient-reported results, increased after the second dose and were better with eptinezumab than with placebo at every time positions.

It is concluded that intravenous administration of eptinezumab provided safe and sustained migraine preventive effects.